Pulnovo Medical

About

Pulnovo Medical is a clinical-stage medical device company developing the Pulmonary Artery Denervation (PADN) System, a first-in-class, minimally invasive radiofrequency ablation therapy targeting overactivated sympathetic nerve activity implicated in pulmonary hypertension and heart failure ¹². The company has performed roughly 1,500 PADN procedures globally and has regulatory approvals in seven countries, with commercialization underway across the European Union, Middle East, and China ¹. In the United States, Pulnovo holds FDA Breakthrough Device designation and has initiated two fully approved Investigational Device Exemption (IDE) trials ¹. Alongside the April 2026 financing, Medtronic and Pulnovo signed a commercial agreement contemplating potential future commercialization opportunities ¹².